Clinical Commander

Back to dossier
symptom.hypercalcemia-workup.v1PRODUCTION
symptom.hypercalcemia-workup.v1

Hypercalcemia evaluation

symptomacutechronicundifferentiatedadultgeriatric
Hard-required inputs
0 / 20
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm hypercalcemia: Ca >10.5 mg/dL (corrected for albumin) OR ionized Ca >1.31 mmol/L; severity stratification (mild <12, moderate 12-14, severe >14 OR symptomatic regardless of level); rule out pseudohypercalcemia (paraproteinemia, falsely elevated)

Inputs
3
Actions
0
Advance rule
Set
Advance when

Hypercalcemia confirmed + severity classified

Patient inputs (35)

Age shifts priors: <50 + asymptomatic hyperCa → consider FHH; ≥50 + de-novo hyperCa → primary hyperPTH most common; ≥60 + severe → malignancy more likely; AACE PMID 28079225 (verify) + NEJM 2017 PMID 28680000 (verify)

Sex shifts priors: female > male for primary hyperPTH (3:1); post-menopausal predominant; certain cancers sex-specific (prostate vs breast / ovarian)

Hypotension from volume depletion (polyuria, vomiting) → IVF emergent; tachycardia + dehydration; hypertensive episodic (pheochromocytoma)

Thiazide diuretic (unmask hyperPTH), lithium (alters Ca-sensing receptor), vitamin D supplementation, calcium carbonate (milk-alkali), vitamin A (retinoids), tamoxifen / aromatase inhibitors, theophylline, ganciclovir; deprescribe + reassess

Known cancer + new hyperCa → likely paraneoplastic; cancer screening status by age + family hx; ~50% of inpatient hypercalcemia is malignancy-related

Family hx hyperCa → consider FHH (autosomal dominant, CASR mutation), MEN-1 (parathyroid + pancreatic + pituitary), MEN-2A (parathyroid + medullary thyroid + pheo), MEN-2B (medullary thyroid + pheo + mucosal neuromas)

Sarcoidosis, TB, histoplasmosis, GPA, berylliosis — granulomatous disease with 1α-hydroxylase activity → elevated 1,25-(OH)2-D; corticosteroids may be needed (PMID 21527617 — verify)

Classic presentation: bones (pain, fractures), stones (kidney stones), abdominal groans (nausea, constipation, peptic ulcer, pancreatitis), psychic moans (confusion, depression, fatigue, weakness); guides severity assessment + diagnosis

Total Ca — confirm hypercalcemia (>10.5 mg/dL); correct for albumin (Corrected Ca = Total Ca + 0.8 × (4 − Albumin)); ionized Ca preferred when available, especially with abnormal protein / acid-base

Albumin correction; if abnormal, ionized Ca more accurate; hypoalbuminemia → falsely low total Ca; multiple myeloma + paraproteinemia → false-positive total Ca

PTH (intact assay) — FIRST diagnostic step after hypercalcemia confirmed; HIGH/normal-high → PTH-dependent (primary hyperPTH, lithium, FHH, MEN, tertiary); LOW/suppressed → PTH-independent (malignancy, granulomatous, vit D toxicity, milk-alkali, hyperthyroid, immobilization)

PO4 — low in primary hyperPTH (PTH wastes PO4); high in vitamin D toxicity, milk-alkali; provides clinical context

Cr + eGFR — AKI common with severe hyperCa (volume depletion + Ca nephrocalcinosis); long-term: CKD progression in primary hyperPTH

25-OH-D — vitamin D toxicity (>150 ng/mL is toxic); deficiency in primary hyperPTH common; replacement complicated

Anemia (myeloma — CRAB), pancytopenia (marrow infiltration), elevated WBC (infection / inflammation)

Alkaline phosphatase — elevated in Paget disease, bone mets, primary hyperPTH (high turnover); LFT for hepatic mets / paraneoplastic

CXR — lung mass (squamous → PTHrP), hilar adenopathy (sarcoid, lymphoma), TB, COPD

ECG — short QT, T-wave changes, AF, bradyarrhythmia in severe; baseline + serial in ED / inpatient

Red flags: altered mental status / seizure / coma → severe; ECG changes (short QT, T-wave, AF, bradyarrhythmia); acute AKI; volume depletion with hypotension; severe Ca >14 even if asymptomatic → ED

Bradyarrhythmia + AF + short QT in severe; ECG essential; cardiac monitoring in severe hyperCa

1,25-(OH)2-D — elevated in granulomatous disease (extra-renal 1α-hydroxylase); lymphoma; primary hyperPTH (also elevated)

PTHrP — elevated in humoral hypercalcemia of malignancy (HHM) — squamous cell, RCC, breast, ovarian; ~80% of malignancy hypercalcemia has elevated PTHrP (PMID 26261118 — verify)

24-h urinary Ca + Ca:Cr ratio — LOW (<0.01) → FHH (do not refer for parathyroidectomy); NORMAL/HIGH → primary hyperPTH; HIGH → vit D toxicity / milk-alkali

SPEP / UPEP / sFLC — multiple myeloma (CRAB: hyperCa, renal, anemia, bone lesions); age ≥50 + anemia + hyperCa → routine screen; route heme.multiple-myeloma.chronic.v1

TSH — hyperthyroidism is rare cause of hyperCa (increased bone turnover); useful in unexplained cases

Plasma fractionated metanephrines or 24-h urinary metanephrines — pheochromocytoma; MEN-2 syndrome screen (hyperCa + medullary thyroid + pheo); route endo.pheochromocytoma.v1

ACE level (sensitivity ~60%, not diagnostic alone), lysozyme — sarcoidosis adjunct; HRCT chest + biopsy diagnostic (PMID 21527617 — verify)

Sestamibi parathyroid scan — localize adenoma in primary hyperPTH for surgical planning; combined with neck US; route endo.hyperparathyroidism.v1

CT C/A/P — occult malignancy (lung, breast, RCC, GI, ovarian, lymphoma); especially if PTH suppressed + B-symptoms + WL

Skeletal survey or PET-CT — lytic bone lesions (myeloma, mets); MRI spine if cord-compression concern

DEXA — osteoporosis (T-score <-2.5) is parathyroidectomy criterion in primary hyperPTH; high turnover from chronic hyperCa

Renal US — nephrolithiasis + nephrocalcinosis from chronic hyperCa; primary hyperPTH parathyroidectomy criterion

Recent prolonged immobilization (especially adolescent, Paget disease, spinal cord injury) → bone resorption > formation

Post-renal-transplant + persistent hyperCa → tertiary hyperPTH; chronic CKD with progression → autonomous PTH; cinacalcet vs parathyroidectomy

Ionized Ca — gold standard when total Ca uncertain (hypoalbuminemia, paraproteinemia, acid-base derangement); normal range 4.65-5.25 mg/dL or 1.15-1.31 mmol/L

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (10)

10 need judgement
  • informationallife_threateningsevere_ca_gt_14_or_symptomatic
    Severe hypercalcemia — Ca >14 mg/dL OR symptomatic (AMS, severe weakness, ECG changes, AKI) regardless of level — EMERGENT IVF NS + calcitonin + bisphosphonate; consider denosumab or HD if refractory (AACE PMID 28079225 — verify)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremalignancy_hypercalcemia_pthrp_lytic_or_vit_d
    Hypercalcemia + suppressed PTH + cancer history OR weight loss + B-symptoms + bone pain — malignancy hyperCa; PTHrP humoral (squamous, RCC, breast, ovarian — PMID 26261118 verify), lytic mets, lymphoma 1,25-D; route oncology + cancer screen
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremultiple_myeloma_crab_features
    Hypercalcemia + CRAB features (renal failure, anemia, bone lesions) + monoclonal protein + age ≥50 — multiple myeloma; route heme.multiple-myeloma.chronic.v1; SPEP / UPEP / sFLC + skeletal survey + bone marrow biopsy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveregranulomatous_sarcoid_tb_1_25_d
    Hypercalcemia + suppressed PTH + elevated 1,25-(OH)2-D + chronic cough + hilar adenopathy + endemic exposure — granulomatous (sarcoid, TB, histoplasmosis, GPA — PMID 21527617 verify); HRCT + biopsy; corticosteroids
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepheochromocytoma_men2_syndrome
    Hypercalcemia + episodic HTN + diaphoresis + palpitations + elevated metanephrines — pheochromocytoma (MEN-2 syndrome — co-occurs medullary thyroid + pheo); route endo.pheochromocytoma.v1; α-block before β-block before surgery
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateprimary_hyperparathyroidism_diagnosis
    Hypercalcemia + elevated PTH (intact assay) + normal renal function + ruling out lithium + family hx — primary hyperPTH; route endo.hyperparathyroidism.v1; sestamibi scan + neck US + parathyroidectomy criteria
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatevitamin_d_toxicity_iatrogenic
    Hypercalcemia + suppressed PTH + elevated 25-OH-D (>150 ng/mL) — vitamin D toxicity (often iatrogenic supplementation); stop vit D + Ca; corticosteroids if severe; long half-life
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatetertiary_hyperparathyroidism_post_transplant
    Hypercalcemia + persistent post-renal-transplant + elevated PTH — tertiary hyperPTH; chronic CKD → autonomous PTH; cinacalcet if Ca >10.2 persistent ≥1 yr post-transplant; parathyroidectomy if severe
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildfamilial_hypocalciuric_hypercalcemia_fhh
    Hypercalcemia + family history + low urinary Ca:Cr ratio <0.01 — FHH (CASR mutation); AVOID parathyroidectomy (does not resolve); genetic counseling; recognition prevents unnecessary surgery
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildthiazide_lithium_drug_induced
    Hypercalcemia + thiazide diuretic OR lithium use + mildly elevated PTH — drug-induced; deprescribe; recheck 4-6 wk; unmask underlying primary hyperPTH common
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

INITIAL_WORKUPrequiredDrives severity classification
Loading…

Recommended regimen

outpatient playbook — drug actions (7)

  1. 1. deprescribe offending agents
    Stop thiazide, lithium, vit D, Ca carbonate, vit A • N/A • immediate + recheck 4-6 wk
    trigger: Drug-induced suspected
    Often unmasks underlying primary hyperPTH; thiazide reduces Ca excretion; lithium alters CaSR; vit D / Ca direct contribution
  2. 2. lifestyle (hydration + avoid supplements)
    Hydration 2-3 L/d; AVOID Ca supplements + vit D supplements unless specifically deficient + replacement needed • PO behavioral • daily
    trigger: All chronic hyperCa workup
    Hydration prevents nephrolithiasis + maintains Ca clearance; supplement avoidance prevents worsening
  3. 3. cinacalcet (for primary hyperPTH if surgery CI, tertiary, parathyroid carcinoma)
    30 mg PO BID, titrate to max 90 mg QID • PO • BID-QID
    trigger: Primary hyperPTH with surgery CI, tertiary hyperPTH post-transplant, parathyroid carcinoma
    CaSR allosteric activator; suppresses PTH; effect in 1-2 wk; nausea common; hypocalcemia risk
  4. 4. bisphosphonate (alendronate for chronic — osteoporosis), zoledronate IV q3-4wk for moderate ongoing
    Alendronate 70 mg PO weekly; OR zoledronate 4 mg IV q3-4 wk • PO / IV • weekly / q3-4 wk
    trigger: Persistent hyperCa with bone disease, osteoporosis in primary hyperPTH
    Adjunct for bone health; not first-line for hyperCa control; renal dose adjust
  5. 5. denosumab (for refractory or bisphosphonate-CI)
    60-120 mg SC q4w • SC • q4w
    trigger: Refractory hyperCa, bisphosphonate CI (eGFR <35)
    RANKL inhibitor; effective in bisphosphonate-refractory; CI in pregnancy
  6. 6. prednisone (for granulomatous / vit D toxicity / lymphoma)
    40-60 mg PO daily; taper over 4-6 wk • PO • daily
    trigger: Granulomatous disease, vitamin D toxicity, lymphoma hypercalcemia
    Reduces 1α-hydroxylase; reduces intestinal Ca absorption; long taper
  7. 7. cause-specific (parathyroidectomy for primary hyperPTH, chemo for malignancy, anti-TB for TB-sarcoid)
    Per disease-specific engine • multimodal • per protocol
    trigger: Cause identified
    Definitive treatment; route to disease-specific engine

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Severe hypercalcemia — Ca >14 mg/dL + altered mental status + ECG changes (short QT, T-wave changes, AF, bradyarrhythmia) — STAT IV NS (200-300 mL/h) + calcitonin 4 IU/kg SC/IM q12h + bisphosphonate (zoledronate 4 mg IV OR pamidronate 60-90 mg IV) OR denosumab 60-120 mg SC if AKI; hemodialysis if severe refractory + AKI; Moderate hypercalcemia — Ca 12-14 mg/dL + symptoms (nausea, polyuria, confusion, weakness, constipation, bone pain) — IVF NS + bisphosphonate (zoledronate 4 mg IV) ± calcitonin if rapid normalization needed; workup cause; Mild hypercalcemia — Ca <12 mg/dL + asymptomatic — outpatient workup; PTH first (PTH-dependent vs independent); CRAB criteria screen for myeloma; thiazide / lithium review.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Hypercalcemia evaluation** (symptom.hypercalcemia-workup.v1).
Phenotype framing: PTH-DEPENDENT (~85% of ambulatory): Primary hyperparathyroidism (~80% ambulatory — adenoma 85%, hyperplasia 15%, carcinoma <1%); Tertiary hyperPTH (post-transplant CKD); Lithium-induced; Familial hypocalciuric hypercalcemia (FHH — CASR mutation); MEN-1, MEN-2A syndromes. PTH-INDEPENDENT (~50% inpatient — most severe): Malignancy (3 mechanisms: PTHrP humoral / lytic bone mets / 1,25-D lymphoma; squamous, RCC, breast, ovarian — PMID 28110218); Granulomatous (sarcoid, TB, histoplasmosis, GPA, berylliosis — PMID 21527617); Vitamin D toxicity (>150 ng/mL 25-OH-D); Vitamin A toxicity; Milk-alkali (Ca carbonate); Hyperthyroidism; Immobilization (Paget, spinal cord injury, adolescent); Pheochromocytoma (MEN-2); Multiple myeloma (CRAB — heme.multiple-myeloma.chronic.v1).
Scope: Confirm hypercalcemia: Ca >10.5 mg/dL (corrected for albumin) OR ionized Ca >1.31 mmol/L; severity stratification (mild <12, moderate 12-14, severe >14 OR symptomatic regardless of level); rule out pseudohypercalcemia (paraproteinemia, falsely elevated)

No severity triggers fired against current inputs.

Plan

No regimen axis selected (engine has no regimen_axes or could not match).

Setting playbook (outpatient) — Cause-anchored hypercalcemia workup for mild (Ca <12) asymptomatic patients: PTH-dependent vs independent classification; route to specific engine; address cause; reassess after intervention
1. deprescribe offending agents Stop thiazide, lithium, vit D, Ca carbonate, vit A N/A immediate + recheck 4-6 wk — Drug-induced suspected (Often unmasks underlying primary hyperPTH; thiazide reduces Ca excretion; lithium alters CaSR; vit D / Ca direct contribution)
2. lifestyle (hydration + avoid supplements) Hydration 2-3 L/d; AVOID Ca supplements + vit D supplements unless specifically deficient + replacement needed PO behavioral daily — All chronic hyperCa workup (Hydration prevents nephrolithiasis + maintains Ca clearance; supplement avoidance prevents worsening)
3. cinacalcet (for primary hyperPTH if surgery CI, tertiary, parathyroid carcinoma) 30 mg PO BID, titrate to max 90 mg QID PO BID-QID — Primary hyperPTH with surgery CI, tertiary hyperPTH post-transplant, parathyroid carcinoma (CaSR allosteric activator; suppresses PTH; effect in 1-2 wk; nausea common; hypocalcemia risk)
4. bisphosphonate (alendronate for chronic — osteoporosis), zoledronate IV q3-4wk for moderate ongoing Alendronate 70 mg PO weekly; OR zoledronate 4 mg IV q3-4 wk PO / IV weekly / q3-4 wk — Persistent hyperCa with bone disease, osteoporosis in primary hyperPTH (Adjunct for bone health; not first-line for hyperCa control; renal dose adjust)
5. denosumab (for refractory or bisphosphonate-CI) 60-120 mg SC q4w SC q4w — Refractory hyperCa, bisphosphonate CI (eGFR <35) (RANKL inhibitor; effective in bisphosphonate-refractory; CI in pregnancy)
6. prednisone (for granulomatous / vit D toxicity / lymphoma) 40-60 mg PO daily; taper over 4-6 wk PO daily — Granulomatous disease, vitamin D toxicity, lymphoma hypercalcemia (Reduces 1α-hydroxylase; reduces intestinal Ca absorption; long taper)
7. cause-specific (parathyroidectomy for primary hyperPTH, chemo for malignancy, anti-TB for TB-sarcoid) Per disease-specific engine multimodal per protocol — Cause identified (Definitive treatment; route to disease-specific engine)

Non-pharmacologic actions:
- Endocrine referral for primary hyperPTH parathyroidectomy candidates (Ca >1 above ULN, eGFR <60, T-score <-2.5, age <50, kidney stones — endo.hyperparathyroidism.v1)
- Genetic counseling for FHH (CASR mutation) — AVOID parathyroidectomy
- Genetic counseling for MEN-1, MEN-2A, MEN-2B
- Oncology referral for malignancy hypercalcemia
- Hematology / oncology for myeloma (route heme.multiple-myeloma.chronic.v1)
- Pulmonary / ID referral for granulomatous disease (sarcoid, TB)
- Nephrology referral for CKD progression in primary hyperPTH or tertiary hyperPTH
- Cardiology referral if arrhythmia history
- Family screening if FHH / MEN identified
- Surgical referral for sestamibi-localized adenoma in primary hyperPTH

Monitoring

Setting (outpatient) monitoring:
- Serum Ca q1-3 mo until stable
- BMP + PO4 + albumin + Cr at each visit
- PTH q3-6 mo (titration of cinacalcet)
- DEXA q1-2 y (osteoporosis monitoring)
- Renal US q1-2 y (nephrocalcinosis)
- Post-parathyroidectomy: Ca + PTH at 6 wk, 6 mo, q12 mo
- Cancer surveillance per oncology
- 25-OH-D q6 mo if low (replace cautiously)
- Symptom diary (bones, stones, groans, moans, psychic)

Follow-up plan: Cause-specific follow-up: parathyroidectomy 6 wk + 6 mo (Ca + PTH); cinacalcet (Ca + PTH + electrolytes q3 mo); cancer surveillance; granulomatous (treat underlying); deprescribing review; lifestyle (hydration, AVOID Ca / vit D supplements unless replacement specifically needed)
- Close-out criterion: Long-term plan + follow-up scheduled

Monitoring phase: ICU: continuous cardiac monitoring, q1-2h Ca + electrolytes, hourly UOP; inpatient: q4-6h Ca, daily BMP, fluid balance; outpatient: q1-3 mo Ca + electrolytes; bisphosphonate response 24-72 h; calcitonin tachyphylaxis 48-72 h; parathyroidectomy follow-up (Ca + PTH q6mo first year); cinacalcet effect (Ca normalization 1-2 wk)

Disposition

Current setting: outpatient — Cause-anchored hypercalcemia workup for mild (Ca <12) asymptomatic patients: PTH-dependent vs independent classification; route to specific engine; address cause; reassess after intervention

Disposition criteria:
- Home (most mild): stepwise outpatient workup + lifestyle + follow-up
- Endocrine: primary hyperPTH parathyroidectomy candidate, complex tertiary, cinacalcet titration
- Oncology: malignancy hyperCa
- Hematology / oncology: multiple myeloma
- Pulmonary / ID: granulomatous disease
- Nephrology: CKD progression, tertiary post-transplant
- ED: severe (>14) or symptomatic or AKI
- Inpatient: requiring bisphosphonate + monitoring

Escalation triggers (move to higher acuity):
- Ca >14 or symptomatic (AMS, severe weakness, ECG changes) → ED for IVF + calcitonin + bisphosphonate
- Acute AKI on outpatient labs → ED
- New severe bone pain or pathologic fracture → emergent imaging + oncology
- New altered mental status → ED
- Severe arrhythmia → ED + cardiac workup
- New diagnosis of malignancy → oncology STAT
- Refractory hyperPTH despite cinacalcet → endocrine surgery referral
- Suspected parathyroid carcinoma → emergent endocrine surgery referral

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Severe hypercalcemia — Ca >14 mg/dL OR symptomatic (AMS, severe weakness, ECG changes, AKI) regardless of level — EMERGENT IVF NS + calcitonin + bisphosphonate; consider denosumab or HD if refractory (AACE PMID 28079225 — verify)
- [SEVERE] Hypercalcemia + suppressed PTH + cancer history OR weight loss + B-symptoms + bone pain — malignancy hyperCa; PTHrP humoral (squamous, RCC, breast, ovarian — PMID 26261118 verify), lytic mets, lymphoma 1,25-D; route oncology + cancer screen
- [SEVERE] Hypercalcemia + CRAB features (renal failure, anemia, bone lesions) + monoclonal protein + age ≥50 — multiple myeloma; route heme.multiple-myeloma.chronic.v1; SPEP / UPEP / sFLC + skeletal survey + bone marrow biopsy

Citations

- AACE hypercalcemia 2017 (PMID 28079225 — verify) + NEJM Hypercalcemia 2017 (PMID 28680000 — verify) + PTHrP malignancy hypercalcemia (PMID 26261118 — verify) + denosumab refractory (PMID 30231007 — verify) + sarcoid hypercalcemia (PMID 21527617 — verify) + paraneoplastic (PMID 28110218) [PMID:28079225](https://pubmed.ncbi.nlm.nih.gov/28079225/)
- Cited evidence (PMID 26261118) [PMID:26261118](https://pubmed.ncbi.nlm.nih.gov/26261118/)
- Cited evidence (PMID 30231007) [PMID:30231007](https://pubmed.ncbi.nlm.nih.gov/30231007/)
- Cited evidence (PMID 28110218) [PMID:28110218](https://pubmed.ncbi.nlm.nih.gov/28110218/)
- Cited evidence (PMID 21527617) [PMID:21527617](https://pubmed.ncbi.nlm.nih.gov/21527617/)

Last reconciled with current guidelines: 2026-05-14.
References
  • AACE hypercalcemia 2017 (PMID 28079225 — verify) + NEJM Hypercalcemia 2017 (PMID 28680000 — verify) + PTHrP malignancy hypercalcemia (PMID 26261118 — verify) + denosumab refractory (PMID 30231007 — verify) + sarcoid hypercalcemia (PMID 21527617 — verify) + paraneoplastic (PMID 28110218) — PMID:28079225
  • Cited evidence (PMID 26261118) — PMID:26261118
  • Cited evidence (PMID 30231007) — PMID:30231007
  • Cited evidence (PMID 28110218) — PMID:28110218
  • Cited evidence (PMID 21527617) — PMID:21527617